A specialty pharmaceutical business with recovering price momentum carries a portfolio of structural weaknesses — cash-burning operations, no measurable competitive moat, a combined growth-plus-margin profile of negative 9, and revenue declining 8% year-over-year — that keep it below the minimum quality threshold required to build a position; the analyst community's implied 51% upside may reflect a turnaround hope that the fundamentals have not yet validated.
Thesis pillars
- Sub Floor Business Quality→Stable
- Revenue Contraction Headwind→Stable
- Back To Back Earnings Misses↑Improving
- +1 more pillar — see the Why tab for full reasoning
Harrow, Inc. (HROW) Stock Analysis
Falling Knife setup
Healthcare · Drug Manufacturers - Specialty & Generic
Sell if holding. Engine safety override at $38.31: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10 and A.R:R 4.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Elevated put/call ratio: 1.39; Below-average business quality.
Harrow is a North American ophthalmic disease management company that markets a broad portfolio of FDA-approved branded eye-care pharmaceuticals, including IHEEZO, VEVYE, TRIESENCE, and biosimilars BYOOVIZ and OPUVIZ, alongside its ImprimisRx compounding pharmacy business... Read more
Sell if holding. Engine safety override at $38.31: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10 and A.R:R 4.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Elevated put/call ratio: 1.39; Below-average business quality. Chart setup: Death cross, below all MAs, RSI 33, MACD bearish. Score 4.3/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.70, earnings proximity 15d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Recent developments
updated 2026-07-26Recent Developments — Harrow, Inc.
Latest news
- NEWS Earnings Preview: Harrow to Report Financial Results Post-market on May 11 - Moomoo — Moomoo neutral
- NEWS Harrow Health (HROW) Reports Q1 Earnings Miss with Shares Down 9 - GuruFocus — GuruFocus negative
- NEWS Is Harrow (HROW) Pricing Reflect Its 65.5% One Year Surge And DCF Outlook - Yahoo Finance — Yahoo Finance positive
- NEWS Harrow Inc. (HROW) Stock Falls on Q1 2026 Earnings - Quiver Quantitative — Quiver Quantitative negative
- NEWS Harrow Inc. (HROW) stock falls on Q1 2026 Earnings - Quiver Quantitative — Quiver Quantitative negative
Generated 2026-07-26T19:57:07Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
5 floor-breakers
Revenue shrinking — -7.6% YoY. Growth thesis broken unless recovery story develops.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Volatile — 6.1% daily ATR makes tight stops impractical. Position-size conservatively.static
Unprofitable operations — net margin -5.6%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $38.31: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.3/10 and A.R:R 4.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Elevated put/call ratio: 1.39; Below-average business quality. Chart setup: Death cross, below all MAs, RSI 33, MACD bearish. Prior stop was $36.97. Score 4.3/10, moderate confidence.
Take-profit target: $58.94 (+53.3% upside). Prior stop was $36.97. Stop-loss: $36.97.
Quality below floor (3.4 < 4.0).
Harrow, Inc. trades at a P/E of N/A (forward 14.4). TrendMatrix value score: 6.8/10. Verdict: Sell.
14 analysts cover HROW with a consensus score of 4.3/5. Average price target: $68.
What does Harrow, Inc. do?Harrow is a North American ophthalmic disease management company that markets a broad portfolio of FDA-approved branded...
Harrow is a North American ophthalmic disease management company that markets a broad portfolio of FDA-approved branded eye-care pharmaceuticals, including IHEEZO, VEVYE, TRIESENCE, and biosimilars BYOOVIZ and OPUVIZ, alongside its ImprimisRx compounding pharmacy business serving more than 10,000 U.S. eyecare prescribers and institutions. Harrow does not manufacture its own branded products, instead relying on third-party contract manufacturers across the U.S., France, Belgium, Spain, and Taiwan, and its revenue depends heavily on reimbursement from Medicare, Medicaid, and commercial payors.